Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

bioAffinity Technologies (BIAF) Operating Income: 2022-2025

Historic Operating Income for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to -$2.3 million.

  • bioAffinity Technologies' Operating Income fell 16.16% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.4 million, marking a year-over-year decrease of 24.35%. This contributed to the annual value of -$9.0 million for FY2024, which is 12.29% down from last year.
  • As of Q3 2025, bioAffinity Technologies' Operating Income stood at -$2.3 million, which was up 8.85% from -$2.5 million recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Operating Income peaked at -$684,119 during Q2 2022, and registered a low of -$2.9 million during Q4 2024.
  • For the 3-year period, bioAffinity Technologies' Operating Income averaged around -$2.2 million, with its median value being -$2.3 million (2025).
  • In the last 5 years, bioAffinity Technologies' Operating Income crashed by 159.95% in 2023 and then climbed by 13.97% in 2024.
  • Quarterly analysis of 4 years shows bioAffinity Technologies' Operating Income stood at -$1.6 million in 2022, then slumped by 44.26% to -$2.3 million in 2023, then declined by 25.79% to -$2.9 million in 2024, then dropped by 16.16% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q3 2025, -$2.5 million for Q2 2025, and -$2.6 million during Q1 2025.